Free Republic

A couple of months ago, effective in November, National Grid, one of Massachusetts’ two dominant utilities, announced rate increases of a “whopping” 37 percent over last year. Other utilities in the region are expected to follow suit. It’s dramatic headlines like these that make rooftop solar sound so attractive to people wanting to save money. In fact, embedded within the online version of the Boston Globe story: “Electric rates in Mass. set to spike this winter,” is a link to another article: “How to install solar power and save.” The solar story points out: “By now everyone knows that solar...

There’s no good time to tell a guy you’re a virgin. First date? Too much, too soon. Wait until the third date and you risk being considered a tease. Second date? Perhaps, but at this point you’re both still fretting over whether or not to eat another piece of bread; delving into sexual histories (or lack thereof) seems a bit extreme. So: There’s no good time to tell a guy you’re a virgin. Even worse? Telling him you’re waiting until marriage.

It’s called the “little pink pill,” a tiny tablet that could have a huge impact on treating female sexual dysfunction. If it’s approved, it would become the first drug of its kind on the market. But that’s a big IF. The drug Flibanserin is locked in a heated battle for approval from the U.S. Food and Drug Administration, raising controversial questions about why there are so many sexual enhancement drugs available for men and zero for women. Cindy Whitehead, the founder and COO of Sprout Pharmaceuticals, a Raleigh, North Carolina-based company focused on producing only Flibanserin, has been fighting for...